# New prostatic cancer trials, last 30 days: 36 (2026)

Updated November 19, 2026.

36 new trials for prostatic cancer were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New prostatic cancer clinical trials, last 30 days: 36 rows for $5, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/new/prostatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945821 | A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors | Coherus Oncology, Inc. | Phase 1/2 | Recruiting | Solid Tumor | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945821) |
| November 17, 2026 | NCT07942220 | Post-ejaculatory Optimization and Physiology of the Seminal Vesicles: A Prospective Paired MRI/CT, Contouring and Dosimetric Pilot Study | University Health Network, Toronto | Not applicable | Not yet recruiting | Prostate Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942220) |
| November 16, 2026 | NCT07940400 | Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer | Wake Forest University Health Sciences | Observational | Not yet recruiting | Prostate Cancer | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940400) |
| November 16, 2026 | NCT07940374 | Quality of Life of Patients Treated by Radiotherapy for Breast and Prostate Carcinoma | Masaryk Memorial Cancer Institute | Not applicable | Completed | Quality of Life, Breast Cancer, Prostate Cancer, Radiotherapy | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940374) |
| November 16, 2026 | NCT07940179 | Access Study Assessing the Safety of Prostate-specific Membrane Antigen Radioligands for Positron Emission Tomography | Sponsor not shown (see the record) | Not applicable | Recruiting | Prostate Cancer, Other Cancers | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940179) |
| November 16, 2026 | NCT07940023 | Bispecific PSMAxCD3 Antibody CC-1 Applied Subcutaneously in Patients With Castration Resistant Prostate Carcinoma | University Hospital Tuebingen | Phase 1 | Not yet recruiting | Castration Resistant Prostate Cancer, Prostate Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940023) |
| November 13, 2026 | NCT07936175 | Pathological Micro-Niches and Multimodal Imaging Macro-Niches for Predicting Clinically Significant Prostate Cancer and Metastasis: A... | Guangxi Medical University | Observational | Active not recruiting | Prostate Cancer, Prostatic Neoplasms | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936175) |
| November 12, 2026 | NCT07934056 | PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging | The First Affiliated Hospital of Soochow University | Early phase 1 | Active not recruiting | Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934056) |
| November 12, 2026 | NCT07932626 | Virtual Reality Education Before CyberKnife Treatment for Prostate Cancer | University Hospital Ostrava | Not applicable | Recruiting | Prostate Cancer Patients | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932626) |
| November 10, 2026 | NCT07928154 | MyPatientPal+: A Smartphone App and a Provider Dashboard to Manage Patient Care While on Treatment | Barbara Ann Karmanos Cancer Institute | Not applicable | Not yet recruiting | Breast Cancer, Gastrointestinal Cancer, Lung Cancer (Diagnosis), Prostate Cancer (Diagnosis), Head and Neck Cancer... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928154) |
| November 10, 2026 | NCT07928037 | A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic... | Novartis Pharmaceuticals | Observational | Not yet recruiting | Metastatic Castration-Resistant Prostate Cancer | 2,045 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928037) |
| November 9, 2026 | NCT07925268 | Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925268) |
| November 9, 2026 | NCT07924644 | AI-Based Digital Pathology Model for Predicting Treatment Response and Prognosis in mHSPC | Xiangya Hospital of Central South University | Not applicable | Active not recruiting | Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | 1,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924644) |
| November 9, 2026 | NCT07924605 | PSMA PET/MRI for Predicting and Detecting Prostate Cancer | University of Wisconsin, Madison | Phase 2 | Not yet recruiting | Prostate Cancer, High-Risk Localized Prostate Cancer, Locally Advanced Prostate Cancer, Low-Risk Prostate Cancer... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924605) |
| November 5, 2026 | NCT07919379 | ProsBiT: Turkish Prostate Biopsy Study | Istanbul Medeniyet University | Observational | Active not recruiting | Prostate Cancer (Adenocarcinoma), Prostatic Neoplams, Prostate Specific Antigen | 8,310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919379) |
| November 5, 2026 | NCT07918235 | Spatial Needle Placement Strategies and Pathological Concordance in Prostate Biopsy: A National Multicenter Retrospective Cohort Study | Guangxi Medical University | Observational | Active not recruiting | Prostate Cancer, Prostatic Neoplasms | 30,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918235) |
| November 4, 2026 | NCT07917390 | ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The... | University of Florida | Phase 1/2 | Not yet recruiting | Prostate Cancer Metastatic to Bone | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917390) |
| November 4, 2026 | NCT07916779 | Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle | University of Zurich | Not applicable | Not yet recruiting | Prostate Cancer, Localized Prostate Carcinoma, Low-Risk Prostate Cancer, Intermediate-risk Prostate Cancer... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916779) |
| November 4, 2026 | NCT07916311 | POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions | Sponsor not shown (see the record) | Not applicable | Not yet recruiting | Prostate Cancer, PI-RADS 3 Prostate Lesion | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916311) |
| November 4, 2026 | NCT07914855 | Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914855) |
| November 2, 2026 | NCT07910019 | Evaluating Prostate Cancer Patient Natural Killer Cell Function Across Racial Background and Addressing Functional Disparities With... | Masonic Cancer Center, University of Minnesota | Observational | Recruiting | Prostate Carcinoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910019) |
| November 2, 2026 | NCT07908407 | Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial | Fred Hutchinson Cancer Center | Not applicable | Not yet recruiting | Bladder Carcinoma, Prostate Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908407) |
| October 30, 2026 | NCT07907653 | Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Prostate Cancer (Adenocarcinoma) | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907653) |
| October 30, 2026 | NCT07906717 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906717) |
| October 29, 2026 | NCT07904026 | Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) | University of Nebraska | Phase 2 | Not yet recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904026) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 7 |
| Phase 3 | 1 |
| Not applicable | 12 |
| Observational | 9 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Guangxi Medical University | 2 |
| Xiangya Hospital of Central South University | 2 |
| National Cancer Institute (NCI) | 2 |
| University of Nebraska | 2 |
| Coherus Oncology, Inc. | 1 |
| University Health Network, Toronto | 1 |
| Wake Forest University Health Sciences | 1 |
| Masaryk Memorial Cancer Institute | 1 |
| University Hospital Tuebingen | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| University Hospital Ostrava | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| University of Wisconsin, Madison | 1 |
| Istanbul Medeniyet University | 1 |
| University of Florida | 1 |
| University of Zurich | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| Haukeland University Hospital | 1 |
| Aristotle University Of Thessaloniki | 1 |
| NYU Langone Health | 1 |
| Aktis Oncology, Inc. | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Periodontics practices in the United States](https://specstream.ai/data/businesses/periodontics-practices/united-states)
- [Criminal defense law firms in the United States](https://specstream.ai/data/businesses/criminal-defense-law-firms/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Financial advisory firms in the United States](https://specstream.ai/data/businesses/financial-advisory-firms/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Importers in the United States](https://specstream.ai/data/businesses/importers/united-states)
